Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colon or Prostate Cancer

The Wnt proteins belong to a family of proteins that have been demonstrated to play a role in the formation and dissemination of tumours. The present project focuses on the critical role of the Wnt-5a protein in the pathobiological processes that lead to metastatic cancer disease.
WntResearch has identified a formylated 6 amino acid peptide fragment, named Foxy-5, which mimick the effects of Wnt-5a to impair migration of epithelial cancer cells and thereby acting anti-metastatic. The aim of the present clinical phase 1 trial is to establish the recommended dose for a clinical phase 2 study and thereby further develop Foxy-5 as a first in class anti-metastatic cancer drug. Foxy-5 is designed to inhibit the development of metastasis by reducing the motility of cancer cells and should thereby increase the survival rates of patients with solid malignant tumours.

Start Date01 Jun 2013

Sponsor / Collaborator

Wntresearch AB

100 Clinical Results associated with Foxy-5

100 Translational Medicine associated with Foxy-5

100 Patents (Medical) associated with Foxy-5

Literatures (Medical) associated with Foxy-5

17 Dec 2024·ACS Omega

Antibacterial Coatings of Poly(ethylenimine)/Poly(l-lactide)-Grafted Hyaluronic Acid Multilayers Surface-Functionalized with Bacteriophages

Article

Author: Urban, Birgit ; Alt, Volker ; Müller, Martin ; Wirth, Luise ; Bittrich, Eva ; Mannala, Gopala-Krishna

The infestation of tissue after implantation is a major problem as a bacterial biofilm can form on the surface of the implants, leading to implant-associated infections (IAIs). One approach to prevent such IAI is to apply antibacterial coatings consisting of polyelectrolyte multilayers (PEM) and bacteriophages (PHAGs). PEM were constructed by alternately adsorbing oppositely charged polyelectrolytes on a substrate according to the layer-by-layer concept. Poly(ethylenimine) (PEI) was used as the cationic polyelectrolyte, and a graft polymer of hyaluronic acid and poly(l-lactide) (DAC) was used as the anionic polyelectrolyte. Comparing PEM-5 (PEI/DAC/PEI/DAC/PEI) and PEM-6 (PEI/DAC/PEI/DAC/PEI/DAC), a higher amount of PHAG was bound to PEM-5 with cationic surface charge, which was detected by atomic force microscopy (AFM) measurements and attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy. The binding of PHAG to the PEM is suggested to be based on electrostatic interactions between the anionic capsid proteins of PHAG and the outermost PEM surface. For antibacterial tests, PEM-5 and PEM-6 each with and without contact to PHAG were deposited at agar plates and infected with bacteria. For the coatings consisting of PEM and PHAG, a significant eradicative effect toward bacteria was obtained, while the pure PEM coatings showed no eradication, which proves the dominant antibacterial contribution originated by PHAG.

14 Aug 2024·Journal of the American Chemical Society

A Cyanine Dye for Highly Specific Recognition of Parallel G-Quadruplex Topology and Its Application in Clinical RNA Detection for Cancer Diagnosis

Article

Author: Liu, Jing ; Li, Qian ; Sun, Ranran ; Yao, Li ; Yang, Dawei ; Zhou, Tianxing ; Bai, Ruiyang ; Xiang, Junfeng ; Sun, Hongxia ; Jiang, Wenna ; Zhang, Boyang ; Zhong, Fanru ; Tang, Yalin

G-quadruplex (G4), an unconventional nucleic acid structure, shows polymorphism in its topological morphology. The parallel G4 topology is the most prevalent form in organisms and plays a regulatory role in many biological processes. Designing fluorescent probes with high specificity for parallel G4s is important but challenging. Herein, a supramolecular assembly of the anionic cyanine dye SCY-5 is reported, which selectively identifies parallel G4 topology. SCY-5 can clearly distinguish parallel G4s from other G4s and non-G4s, even including hybrid-type G4s with parallel characteristics. The high specificity mechanism of SCY-5 involves a delicate balance between electrostatic repulsion and π-π interaction between SCY-5 and G4s. Using SCY-5, cellular RNA extracted from peripheral venous blood was quantitatively detected, and a remarkable increase in RNA G4 content in cancer patients compared to healthy volunteers was confirmed for the first time. This study provides new insights for designing specific probes for parallel G4 topology and opens a new path for clinical cancer diagnosis using RNA G4 as a biomarker.

01 Jul 2024·Ophthalmic and Physiological Optics

Assessing neophyte response to daily disposable silicone hydrogel contact lenses: A randomised clinical trial investigation over one month

Article

Author: Garcia-Queiruga, Jacobo ; Giraldez, Maria J ; Noya-Padin, Veronica ; Pena-Verdeal, Hugo ; Yebra-Pimentel, Eva ; Ferreiro-Figueiras, Dolores

AbstractObjectiveThis randomised clinical trial assessed the impact on symptoms, tear film dynamics and ocular surface integrity of daily disposable silicone‐hydrogel contact lenses (CLs) over a month, paying special attention to lid wiper epitheliopathy (LWE) and its implications for CL discomfort.MethodsNeophyte CL wearers (n = 44, 21.09 ± 5.00 years old) were randomly assigned to either the experimental (n = 24) or control group (n = 20). Participants assigned to the experimental group were required to wear daily disposable CLs for 1 month for at least 8 h/day and 6 days/week. All participants were healthy subjects (no history of ocular surgery or active ocular disease) with spherical refractive errors between −8.00 and +5.00 D and cylindrical power <0.75 D. At the baseline and 1‐month sessions, the Dry Eye Questionnaire 5 (DEQ‐5) was completed, together with the measurement of tear film osmolarity with the TearLab osmometer, tear meniscus height (TMH) and lipid layer pattern (LLP) using a slit‐lamp with Tearscope Plus attached, fluorescein break‐up time (FBUT), maximum blink interval (MBI), corneal staining with fluorescein under cobalt blue light and LWE with lissamine green under slit lamp and halogen white light.ResultsAt the baseline session, LWE showed a negative correlation with DEQ‐5 (r = −0.37, p = 0.02). Significant differences in FBUT and LWE (p = 0.04) and a positive correlation between LWE and DEQ‐5 (r = 0.49, p = 0.007) were observed at 1 month. Intrasession analysis at 1 month showed significant differences between the experimental and control groups in DEQ‐5, FBUT and LWE (all p ≤ 0.02). Intersession analysis in the experimental group showed variations in DEQ‐5, FBUT and LWE (all p ≤ 0.02) but no significant variation in the control group (all p ≥ 0.11).ConclusionThe presence of LWE was significantly correlated with higher symptom values in the DEQ‐5. Also, participants in the experimental group presented higher values of LWE after 1 month of CL wear, in comparison with the control group.

100 Deals associated with Foxy-5

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB13034

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colonic Cancer	Phase 2	ES	Wntresearch AB	12 Apr 2019
Metastatic colon cancer	Phase 2	DK	Wntresearch AB	01 Apr 2016
Metastatic colon cancer	Phase 2	GB	Wntresearch AB	01 Apr 2016
Metastatic Prostate Carcinoma	Phase 2	DK	Wntresearch AB	01 Apr 2016
Metastatic Prostate Carcinoma	Phase 2	GB	Wntresearch AB	01 Apr 2016
Neoplasm Metastasis	Phase 2	GB	Wntresearch AB	01 Apr 2016
Neoplasm Metastasis	Phase 2	DK	Wntresearch AB	01 Apr 2016
Metastatic breast cancer	Phase 2	DK	Wntresearch AB	01 Jun 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EUCTR2018-003074-27-ES (NeoFox, ESMO_GI2024) Manual	Phase 2	Colonic Cancer Neoadjuvant	110	Foxy-5	(hfiromophj) = The pathological examination of primary tumours revealed that significantly fewer patients treated with Foxy-5 exhibited venous invasion of cancer cells (p=0.0097) as well as perineural invasion (p=0.0088) moesqobuea (psafmeispv ) View more	Positive	26 Jun 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Foxy-5

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation